Treatment of Severe Influenza A Infection

Status Completed

Clinical Trial Summary

Each year, influenza A infection caused great mortality and morbidity, especially among the elderly and individuals with chronic illness. Many of these patients are 'late presenters' who are admitted to hospital a few days after symptoms onset and have developed complications secondary to immunodysregulation. Antiviral treatment with the neuraminidase inhibitor is of limited usage for patients who presented to the hospital 48 hours after symptom onset. Apart from ventilatory and extracorporeal membrane oxygenation support, treatment options for these patients are limited. Recent animal study has demonstrated that combinations of an antiviral agent with a COX-II inhibitor can reduce mortality in mice infected with influenza virus. The investigators therefore propose to enrol patients with severe influenza A infection requiring hospitalization and oxygen support on a randomized controlled trial with celecoxib.

Clinical Trial Description

The aim of this double blind randomized controlled trial is to compare the clinical efficacy and safety of celecoxib combined with neuraminidase inhibitors in patients with severe influenza A infection. The hypothesis of this study is that treatment of severe influenza A infection with celecoxib will reduce mortality. The primary outcome to be assessed will be the 28-days mortality rate from hospitalization. The secondary outcomes to be assessed will be safety of the treatment, duration of intensive care, duration of ventilatory and oxygen support, the viral load and cytokine change. ;

Study Design

Related Conditions & MeSH terms

Influenza, Human

Clinical Trial Details

NCT number	NCT02108366
Study type	Interventional
Source	The University of Hong Kong
Contact
Status	Completed
Phase	Phase 3
Start date	March 2014
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03442582` - Afluria Pregnancy Registry
Completed	`NCT03275389` - A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years	Phase 1
Completed	`NCT05981846` - A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19	Phase 2
Completed	`NCT05044195` - A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age	Phase 3
Completed	`NCT02914275` - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.	Phase 3
Completed	`NCT04590066` - Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy	N/A
Recruiting	`NCT03778203` - Development of Childhood Anti-influenza Immunity	Phase 4
Completed	`NCT04527614` - Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection	N/A
Terminated	`NCT03658629` - Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults	Phase 2
Completed	`NCT05269290` - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections	Phase 3
Completed	`NCT06385821` - A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus	Phase 3
Completed	`NCT02867358` - A Clinical Trial of KT07 Capsule in the U.S.A	Phase 2
Completed	`NCT02998996` - Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU	Phase 1/Phase 2
Withdrawn	`NCT02883972` - Childhood Influenza Immunisation Invitation Trial in Schools	N/A
Completed	`NCT02984280` - Specific Respiratory Infections as Triggers of Acute Medical Events	N/A
Completed	`NCT02545543` - A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age	Phase 3
Completed	`NCT02621164` - Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents	Phase 3
Completed	`NCT02212106` - A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years	Phase 4
Completed	`NCT02243774` - Mail Outreach To Increase Vaccination Acceptance Through Engagement	N/A
Completed	`NCT02344134` - Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects	Phase 3